Biocare Hepaguard Forte Vegetable - Pack of 60 Capsules

Product Information

Low risk of bias: the trial reported the following pre‐defined outcomes: at least one of the outcomes related to the main reason for treatment of people with NAFLD, namely, all‐cause mortality or resolution of NAFLD, along with adverse events. Nutritional supplementation has the potential to result in resolution or decreased progression of fatty liver disease.

BioCare Antioxidant Complex has recently been re-formulated with increased levels of green tea, turmeric and Vitaflavan® grapeseed extract, alongside other potent phytonutrients such as quercetin, lycopene, lutein and high strength bilberry extract.However, people taking PUFA (polyunsaturated fatty acid) may be more likely to experience an adverse event than those not receiving an active intervention (network meta‐analysis results: OR 4. Number of participants with events for binary outcomes, mean and standard deviation for continuous outcomes, numbers of events and mean follow‐up period for count outcomes, and numbers of participants with events and mean follow‐up period for time‐to‐event outcomes. Choline is an essential phospholipid which supports liver function and lipid metabolism, whilst artichoke and milk thistle are potent herbs which aid digestion (especially of fats), detoxification, and liver and gallbladder health.

To find out if any form of nutritional supplementation decreases effects of non‐alcohol‐related fatty liver disease on lifespan, health‐related quality of life, chronic liver disease, and its complications, and whether nutritional supplementation causes any harm.We used a 'burn‐in' of 30,000 simulations, checked for convergence (of effect estimates and between‐study heterogeneity) visually (i.

Phosphatidylcholine is a precursor of choline and one of the main components of lipoproteins in blood circulation and cell membranes. However, it must be noted that existing non‐invasive tests to distinguish NAFLD from alcohol‐related liver disease (ALD) are only about 75% to 90% accurate, and some individuals with ALD may be mis‐classified as having NAFLD ( Cerovic 2013; Wang 2016). In the HEPAGUARD complex, carefully selected components such as cardoon, artichoke and lactulose are combined with one another. For the random‐effects model, we used a prior distributed uniformly (limits: 0 to 5) for the between‐trial standard deviation parameter and assumed that this variability would be the same across treatment comparisons ( Dias 2016).In 9 trials, all participants were females ( Abdelmalek 2009; Panahi 2012; Amiri‐Moghadam 2015; Orr 2015; Hosseini 2018; Kobyliak 2018; Lewis 2018; Hoseini 2020; Moradi 2020). Fatty liver disease is steatosis (accumulation of fat, usually triglycerides) in the liver parenchymal cells ( NCBI 2018).

The evidence is very uncertain about effects of interventions on serious adverse events (number of people or number of events). We considered a trial to be at low risk of bias if we assessed the trial to be at low risk of bias across all listed bias risk domains. We estimated the probability that each intervention was ranked at each of the possible positions based on estimated effect sizes and their corresponding uncertainty using the NICE DSU codes ( Dias 2016). After a mean follow‐up period of 8 to 28 years, the presence of NAFLD was noted to increase overall long‐term mortality compared to the general population without NAFLD ( Adams 2005; Bedogni 2007; Ong 2008; Soderberg 2010; Onnerhag 2014).HepaGuard Forte is a specialist combination including choline bitartrate, inositol, sodium sulphate, artichoke extract, L-taurine, apple extract and L-methionine. A possible reason for complications of liver disease being rare in trial participants may be the short follow‐up period given in these trials (participants were followed only for a period of 2 months to 28 months). This complex has antioxidant benefits to support liver cell health and helps maintain normal glutathione levels.